辅助治疗方案.pdf

1、Adjuvant Treatment OptionsNaomi B.Haas,MDAbramson Cancer CenterWhat have we learned from adjuvant therapy trials?Adjuvant pembrolizumab improved DFS and OS in pre-specified ccRCC at high and very high risk for recurrenceKnowledge gaps Duration of therapy needed is not defined Identification of patie

2、nt populations who dont need adjuvant therapy or should get more intensive therapy requires more work Markers such as KIM-1 in post hoc analyses show potential benefits to high KIM-1 patient populations treated with pembrolizumab,nivolumab and atezolizumab Does targeting additional mechanisms improv

3、e outcomes?Does neoadjuvant therapy work in RCC?The lack of benefit to perioperative nivolumab in PROSPER RCC but existing benefit of neoadjuvant ICIs in melanoma,NSCLC,and other solid tumors prompts more work in the neoadjuvant spaceRecently completed trials with pending results RAMPART Phase III R

4、andomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary RCC at High or Intermediate Risk of Relapse of durvalumab+/-tremelimumab can improve Disease Free Survival(DFS)or Overall Survival(OS)compared to the current global standard-of-care(active monitoring)NCT0328853

5、2 Litespark-022 Adjuvant Pembrolizumab+/-Belzutifan INTerpath-004 Adjuvant Intismeran Autogene(V940)+Pembrolizumab in RCC NCT06307431 Vorolanib+/-Toripalimab(VEGFR-TKI+ICI)as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma NCT07047001 EXCLUSION ZONESLI

6、DE DIMENSIONS SHOULD FOLLOW 16:9 RATIORAMPART1750 ptsPDL-1i+/-CTLA4iVs active monitoringLitespark-022INTerpath-004 Adjuvant Intismeran Autogene(V940)+Pembrolizumab in RCC NCT06307431Ongoing Adjuvant TrialsccRCC STRIKE A032201 Intensified pembrolizumab and tivozanib for high risk ccRCC NCT06671912 TU